{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"42","upperLimit":"78","value":"60"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"}],"units":"Participants"}],"description":"Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.\n\nThe primary endpoint of 2-year progression-free survival was measured from the date of enrollment to the first occurrence of new metastatic lesion, objective tumor progression, or death.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nab-Paclitaxel, Cisplatin, Cetuximab, intensity-modulated radiation therapy\n\nCetuximab: Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor\n\nCisplatin: Cisplatin is an anti-cancer chemotherapy drug\n\nNab-Paclitaxel: paclitaxel albumin-stabilized nanoparticle formulation\n\nintensity-modulated radiation therapy: intensity-modulated radiation therapy","id":"OG000","title":"Phase II Nab-Paclitaxel, Cisplatin, Cetuximab and Radiotherapy"}],"paramType":"NUMBER","populationDescription":"12 patients from Phase I also participated in Phase II of this study. 25 patients enrolled in the phase II study with 3 patients withdrew from the study prior to treatment.","reportingStatus":"POSTED","timeFrame":"2 year","title":"Phase II 2-year Progression-free Survival","type":"PRIMARY","unitOfMeasure":"percentage of participants"}